Successful combination treatment with bevacizumab, thalidomide and autologous PBSC for severe POEMS syndrome
Authors:
- 1 December 2008
- journal article
- letter
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 43 (9) , 739-740
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndromeJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndromeEuropean Journal of Haematology, 2008
- Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndromeAnnals of Oncology, 2008
- POEMS syndromeBlood Reviews, 2007
- Treatment of POEMS syndrome with bevacizumabHaematologica, 2007
- Failure of Treatment with Anti-VEGF Monoclonal Antibody for Long-standing POEMS SyndromeInternal Medicine, 2007
- Bevacizumab therapy for POEMS syndromeBlood, 2006
- Bevacizumab therapy for POEMS syndromeBlood, 2005
- Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood, 2005
- Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literatureBlood, 2004